K. Robinson

Development and evaluation of a patient decision aid for patients considering ongoing medical or surgical treatment options for ulcerative colitis using a mixed-methods approach: protocol for DISCUSS study

Steven R. Brown, S. Sebastian, A. Lobo, 2020, BMJ Open.

Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls

R. Sidhu, D. Sanders, M. McAlindon, 2007, Scandinavian journal of gastroenterology.

Prodromal Irritable Bowel Syndrome May Be Responsible for Delays in Diagnosis in Patients Presenting with Unrecognized Crohn’s Disease and Celiac Disease, but Not Ulcerative Colitis

D. Sanders, M. McAlindon, A. Lobo, 2011, Digestive Diseases and Sciences.

High prevalence of antibodies to infliximab and their relation to clinical outcomes in inflammatory bowel disease patients

A. Lobo, R. Sargur, M. Hale, 2019, GastroHep.

Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease

D. Sanders, M. McAlindon, P. Shah, 2011, European journal of gastroenterology & hepatology.

Outcome of elective withdrawal of anti-tumour necrosis factor-&agr; therapy in patients with Crohn's disease in established remission*

S. Cross, M. McAlindon, S. Sebastian, 2014, Journal of Crohn's & colitis.

P392 Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study

M. McAlindon, S. Sebastian, A. Lobo, 2013 .

A survey of patient informational preferences when choosing between medical and surgical therapy for ulcerative colitis: a sub‐study from the DISCUSS project

A. Lobo, D. Baker, A. Folan, 2023, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

N803 Accelerated infusions of biosimilar infliximab are safe and well tolerated and monitoring post-infusion is not required.

K. Robinson, A. Wright, A. Lobo, 2017, Journal of Crohn's & colitis.

The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab

A. Lobo, L. Marshall, R. Sargur, 2021, European journal of gastroenterology & hepatology.

Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease

D. Sanders, M. McAlindon, P. Shah, 2011, European journal of gastroenterology & hepatology.